-
Expression levels of genes implicated in the working mechanism of lenalidomide predict treatment response in lower risk myelodysplastic syndrome patients
In 't Hout, F. E. M., Scheele, T. N., Westers, T. M., Alhan, C., Duetz, C., Cremers, E. M. P., Visser-Wisselaar, H. A., Verbrugge, A., Chitu, D. A., Van der Reijden, B. A., De Graaf, A. O., Jansen, J. H. & van de Loosdrecht, A. A., 10 Oct 2024, (E-pub ahead of print) In: Haematologica.Research output: Contribution to journal › Article* › Academic › peer-review
-
Determinants of lenalidomide response with or without erythropoiesis-stimulating agents in myelodysplastic syndromes: the HOVON89 trial
van de Loosdrecht, A. A., Cremers, E. M. P., Alhan, C., Duetz, C., in ’t Hout, F. E. M., Visser-Wisselaar, H. A., Chitu, D. A., Verbrugge, A., Cunha, S. M., Ossenkoppele, G. J., Janssen, J. J. W. M., Klein, S. K., Vellenga, E., Huls, G. A., Muus, P., Langemeijer, S. M. C., de Greef, G. E., te Boekhorst, P. A. W., Raaijmakers, M. H. G. & van Marwijk Kooy, M. & 20 others, , Apr 2024, In: Leukemia. 38, 4, p. 840-850 11 p.Research output: Contribution to journal › Article* › Academic › peer-review
-
Dysplasia and PNH-type cells in bone marrow aspirates of myelodysplastic syndromes
Westers, T. M., Alhan, C., Visser-Wisselaar, H. A., Chitu, D. A. & van de Loosdrecht, A. A., 1 Mar 2023, In: Cytometry. Part B, Clinical cytometry. 104, 2, p. 162-172Research output: Contribution to journal › Article* › Academic › peer-review
- All publications
